Carboprost (Hemabate) for Fibroid Resection

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Carboprost; Carboprost tromethamine

Criteria

Inclusion Criteria:

• Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery

• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

• If any oxytocic agents have been or will be administered prior to surgery

• History of renal and/or hepatic impairment

• Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID)

• Anemia (Hgb < 7g/dL), diabetes mellitus, jaundice, or epilepsy